Namzaric is a once-daily, fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist), and donepezil hydrochloride (an acetylcholinesterase inhibitor). Last December, the US Food and Drug Administration
The collaboration also aligns with Genzyme’s early-stage MS research programs involving neuroprotection and CNS repair. The neurodegeneration observed in MS is not directly targeted by currently available treatments
The new Swedish facility will supply medicines for clinical trial programs of AstraZeneca and its R&D arm MedImmune from end of 2018 and will deliver finished products for
The company said that the new Berinert 1500 IU format is reconstituted with 3mL vial of Sterile Water for Injection (Diluent). In Canada, Berinert is indicated to treat
Safinamide is a new chemical entity and it has unique mode of action including selective and reversible MAO-B-inhibition and blocking of voltage dependent sodium channels which leads to
The drug is indicated for NSCLC patients who have failed two prior lines of therapy to show a clinically important and statistically robust improvement in overall survival over
The approval marks the first approved combination and first approved sumatriptan migraine product for patients aged 12-17 years. The company said that the two medicines sumatriptan and naproxen
ALN-AAT is a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT). The company said that ALN-AAT employs its Enhanced Stabilization Chemistry (ESC)-GalNAc delivery technology. The proposed clinical
HS, referred to as acne inversa, is a painful, chronic inflammatory skin disease for which there is no known cure and no approved medication. It is characterized by
The company said that additional site approval comes amid increased industry demand for sterile Intravenous (IV) solutions The approval includes product presentations in 250mL, 500mL and 1000mL, which
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.